Becker's Hospital Review

Lexicon earns FDA approval for carcinoid syndrome diarrhea drug

Carcinoid syndrome is a rare condition that occurs in patients with gastrointestinal tumors. These patients secrete an excessive amount of serotonin, which can lead to symptoms like frequent diarrhea, ...
Nasdaq

Amryt's Mycapssa Gets Orphan Drug Status For Treatment Of Carcinoid Syndrome

(RTTNews) - Amryt (AMYT) on Thursday said the Food and Drug Administration has granted Orphan Drug Designation to its Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome is a set of ...
Seeking Alpha

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community ...
ascopubs.org

Serotonin synthesis inhibitors: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome.

Intratumoral conversion of flucytosine to 5-fluorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (Toca 511) in an immune-competent model of ...
Business Insider

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK ...
ascopubs.org

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study.

Assessment of the 7th edition of the AJCC classification and a proposal of a new classification in patients with gastric cancer undergoing D2 gastrectomy. This is an ASCO Meeting Abstract from the ...
Seeking Alpha

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) ...
Yahoo Finance

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, ...